Martin Lukáš

Charles University — Czech Republic

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.1kcitations114works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(62), Microscopic Colitis(32), Biosimilars and Bioanalytical Methods(18), Diverticular Disease and Complications(13), Autoimmune and Inflammatory Disorders(9)

Publications106 total

Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study
Therapeutic Advances in Gastroenterology·2025Open Access
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class
Journal of Crohn s and Colitis·2025
VEDOLIZUMAB PLUS CURCUMIN-QINGDAI FOR PATIENTS WITH ULCERATIVE COLITIS
Gastroenterology·2025
VEDOLIZUMAB PLUS CURCUMIN-QINGDAI FOR PATIENTS WITH ULCERATIVE COLITIS
Inflammatory Bowel Diseases·2025· 1 citedOpen Access
Contributors
Elsevier eBooks·2025
Porcine Model of Anastomotic Stricture in Crohn’s Disease
Elsevier eBooks·2025
DOP047 Effectiveness of second-and-third line biologics in perianal Crohn’s disease (pCD) – a multicenter propensity score-matched study
Journal of Crohn s and Colitis·2025
P0873 Risk factors for difficult endoscopic bowel dilatation of strictures among patients with inflammatory bowel disease (IBD): Findings from a IBD tertiary centers in Poland and Czech Republic
Journal of Crohn s and Colitis·2025
P0979 Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn’s disease: A retrospective, mul-ticenter study
Journal of Crohn s and Colitis·2025Open Access
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
The Lancet·2024· 77 citedOpen Access
Wirksamkeit und Sicherheit von subkutanem Infliximab nach immunogenem Wirkversagen auf intravenöses Infliximab bei Morbus Crohn Patient*innen
Zeitschrift für Gastroenterologie·2024
EFFICIENCY AND SAFETY OF SELF-EXPANDIBLE METALLIC STENT (SEMS) PLACEMENT IN CROHN’S DISEASE STRICTURES
Gastrointestinal Endoscopy·2024
EFFICIENCY AND SAFETY OF SELF-EXPANDIBLE METALLIC STENT (SEMS) PLACEMENT IN CROHN’S DISEASE STRICTURES
Gastrointestinal Endoscopy·2024
Efficiency and safety of self-expandible metallic stent (SEMS) placement in Crohn’s disease strictures
Endoscopy·2024
P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure
Journal of Crohn s and Colitis·2024Open Access
Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
Gastroenterologie a hepatologie·2023
Endoscopic stricturotomy – A novel therapeutic modality for IBD-related strictures: First European experience
Endoscopy·2023
LONGITUDINAL COMPRESSION THERAPY FOR SMALL BOWEL STRICTURE CROHN’S DISEASE: DURABLE RESOLUTION IN SWINE MODEL
Gastroenterology·2023Open Access
LONGITUDINAL COMPRESSION THERAPY FOR SMALL BOWEL STRICTURE CROHN'S DISEASE: DURABLE RESOLUTION IN SWINE MODEL
Inflammatory Bowel Diseases·2023Open Access
Porcine Model of Anastomotic Stricture in Crohn’s Disease
Gastrointestinal Endoscopy Clinics of North America·2022
page 1 of 6Next →

Frequent Co-authors

Milan Lukáš(39), Martin Bortlík(37), Dana Ďuricová(34), Naděžda Machková(31), Veronika Hrubá(30), Karin Malíčková(28), Martin Kolář(28), Katarína Mitrová(22), Martin Vašátko(14), Karolína Pudilová(5), Bo Shen(4), Péter L. Lakatos(4), Tamás Molnár(4), Radka Vaníčková(4), Gursimran Kochhar(3), Udayakumar Navaneethan(3), Francis A. Farraye(3), David A. Schwartz(3), David H. Bruining(3), William J. Sandborn(3)